Veradigm to Acquire ScienceIO

Veradigm Acquires Koha Health

January 2, 2024

Healthcare Services

Veradigm Inc. (NASDAQ: MDRX) has acquired Koha Health, a full-service revenue cycle management (RCM) company, to expand its ambulatory revenue cycle services and add Musculoskeletal (MSK) specialty expertise. The acquisition strengthens Veradigm’s end-to-end RCM capabilities for ambulatory provider practices and ambulatory surgical centers (ASCs) across multiple EHR systems.

Medtronic to Acquire Scientia Vascular for $550 Million

March 10, 2026

Medical Devices

Medtronic entered into a definitive agreement to acquire Scientia Vascular, valuing the deal at $550 million (subject to customary adjustments), with potential earn-out and milestone payments. The acquisition is intended to expand Medtronic’s neurovascular portfolio by combining its therapeutic technologies with Scientia’s access products (guidewires and catheters) for complex neurovascular procedures.

Exact Sciences Acquires Paradigm Diagnostics and Viomics

March 3, 2020

Healthcare Services

Exact Sciences Corp. has completed the acquisitions of Phoenix-based Paradigm Diagnostics, Inc. and Viomics, Inc., adding a late-stage therapy selection genomic profiling test, a scalable clinical lab, and sequencing/biomarker discovery capabilities to its precision oncology portfolio. The deals (financial terms largely undisclosed in the company release) bring Paradigm and Viomics into Exact Sciences’ research and commercial platform to accelerate tissue- and blood-based advanced cancer diagnostics.

Veracyte to Acquire C2i Genomics to Add Whole-Genome MRD Capabilities

January 8, 2024

Healthcare Services

Veracyte has reached a definitive agreement to acquire C2i Genomics, a minimal residual disease (MRD) detection company, to add whole-genome MRD capabilities to its diagnostics platform. Under the terms, Veracyte will pay $70 million in Veracyte shares at closing and up to an additional $25 million tied to future performance milestones, expected to close in the first quarter of 2024.

Sorcero Acquires Axiom Health

July 16, 2025

AI & Machine Learning

Sorcero, an AI-driven life sciences analytics company, has acquired Axiom Health, a real-world data platform focused on the medical technology industry. The Axiom Health platform will be rebranded as Sorcero MedTech to unify medtech and pharmaceutical insights; the transaction was supported by a new investment from First Trust Capital Partners and additional investments from Axiom investors.

Merck Acquires Imago BioSciences for $1.35 Billion

November 21, 2022

Biotechnology

Merck (MSD) entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Imago BioSciences in an all-cash deal valued at approximately $1.35 billion (=$36.00 per share). Merck will commence a tender offer for all outstanding shares, with the transaction expected to close in the first quarter of 2023, subject to customary conditions.